Plocamium Global Insights
Gilead Sciences secured a rare commercial advantage on May 22, 2026, when the FDA approved Hepcludex (bulevirtide-gmod) as the first treatment for chronic hepatitis delta virus infection in adults—ending a decades-long therapeutic drought for a disease that accelerates liver failure faster than hepa
429 episodes
Comments
0Be the first to comment
Sign up now and become a member of the Plocamium Global Insights community!